Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the Market Potential of Jazz Pharma's JZP-110 for the treatment of Obstructive Sleep Apnea (OSA) and Narcolepsy and how it compares to Xyrem

Ticker(s): JAZZ, AVDL

Who's the expert?

Name: Dr Alberto Ramos - MD

Institution: University of Miami

  • Associate Professor of Clinical Neurology and Co-Director of the Sleep Disorders program at the University of Miami, Miller School of Medicine. 
  • Treats hundreds of patients with OSA & 20 patients with narcolepsy and is Board certified in both Neurology and Sleep Medicine.
  • Research focus is on sleep and cerebrovascular disease in population based studies. He has been involved in a number of NIH sponsored studies in this area an is currently working on the K12 research study at the Miller School of Medicine evaluating cerebral hemodynamics and impaired cerebral vasomotor reactivity in obstructive sleep apnea within the Hispanic Community.


Interview Questions

Please describe your current practice. How many patients do you treat with OSA? With Narcolepsy?

Added By: c_admin

Is Hetlioz mechanistically superior in treating non24 compared to regular melatonin?

Added By: c_admin

How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?

Added By: c_admin

Is there anything else on the horizon for OSA that you think is promising?

Added By: c_admin

On a scale from 1-10, where would you put your level of excitement for JZP-110?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.